The estimated Net Worth of Paul Herendeen is at least $7.09 Milion dollars as of 9 September 2022. Mr. Herendeen owns over 10,000 units of Bausch Health Companies Inc stock worth over $110,419 and over the last 10 years he sold BHC stock worth over $0. In addition, he makes $6,977,360 as Chief Financial Officer a Executive Vice President at Bausch Health Companies Inc.
Sign up
Mr. Herendeen BHC stock SEC Form 4 insiders trading
Paul has made over 5 trades of the Bausch Health Companies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of BHC stock worth $150,300 on 9 September 2022.
The largest trade he's ever made was exercising 49,324 units of Bausch Health Companies Inc stock on 8 March 2021 worth over $314,687. On average, Paul trades about 3,385 units every 63 days since 2014. As of 9 September 2022 he still owns at least 17,307 units of Bausch Health Companies Inc stock.
You can see the complete history of Mr. Herendeen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Herendeen biography
Paul S. Herendeen is Chief Financial Officer, Executive Vice President of the company. Prior to joining Bausch Health, he served as Executive Vice President and CFO of Zoetis Inc. for two years. From 2005 to 2013 and from 1998 to 2001, Mr. Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe Pharmaceuticals, a privately held healthcare company, where he served as CFO from 2001 until 2005. Prior to that, Mr. Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation and as a senior auditor with Arthur Andersen & Company. Mr. Herendeen earned a Master of Business Administration from the University of Virginia’s Darden School of Business and holds a bachelor’s degree in Business Administration from Boston College.
What is the salary of Paul Herendeen?
As the Chief Financial Officer a Executive Vice President of Bausch Health Companies Inc, the total compensation of Paul Herendeen at Bausch Health Companies Inc is $6,977,360. There are 1 executives at Bausch Health Companies Inc getting paid more, with Joseph Papa having the highest compensation of $17,141,600.
How old is Paul Herendeen?
Paul Herendeen is 64, he's been the Chief Financial Officer a Executive Vice President of Bausch Health Companies Inc since 2016. There are 7 older and 13 younger executives at Bausch Health Companies Inc. The oldest executive at Bausch Health Companies Inc is Richard De Schutter, 79, who is the Independent Director.
What's Paul Herendeen's mailing address?
Paul's mailing address filed with the SEC is C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD, IN, 46140.
Insiders trading at Bausch Health Companies Inc
Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas a Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.
What does Bausch Health Companies Inc do?
bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
What does Bausch Health Companies Inc's logo look like?
Complete history of Mr. Herendeen stock trades at Zoetis Inc, Elanco Animal Health Inc a Bausch Health Companies Inc
Bausch Health Companies Inc executives and stock owners
Bausch Health Companies Inc executives and other stock owners filed with the SEC include:
-
Joseph Papa,
Chairman of the Board, Chief Executive Officer -
Paul Herendeen,
Chief Financial Officer, Executive Vice President -
Joseph C. Papa,
CEO & Chairman -
Thomas Appio,
President & Co-Head Bausch + Lomb/International -
William Humphries,
-
Christina Ackermann,
Executive Vice President, General Counsel -
Thomas J. Appio,
Pres & Co-Head Bausch + Lomb/International -
Paul S. Herendeen,
Exec. VP and Advisor to Chairman & CEO -
Joseph Gordon,
President & Co-Head Bausch + Lomb/International -
Christina M. Ackermann,
Exec. VP, Gen. Counsel & Head of Commercial Operations -
Thomas Ross,
Lead Independent Director -
Russel Robertson,
Independent Director -
Robert Power,
Independent Director -
Argeris Karabelas,
Independent Director -
Sarah Kavanagh,
Independent Director -
D. Robert Hale,
Independent Director -
Amy Wechsler,
Independent Director -
Richard De Schutter,
Independent Director -
Andrew Charles von Eschenbach,
Independent Director -
John Paulson,
Independent Director -
Tom G. Vadaketh,
Chief Financial Officer -
Frederick J. Munsch,
Controller & Chief Accounting Officer -
Kelly Webber,
Sr. VP & Chief HR Officer -
Stacey Williams,
VP of Marketing -
Michael McMyne,
VP of Sales -
Arthur J. Shannon,
Sr. VP and Head of Investor Relations & Communications -
Dr. Robert F. Butz,
VP of Medical & Scientific Affairs -
Osama A. Eldessouky,
CFO & Exec. VP -
Christian A Garcia,
Director -
Frank D. Lee,
Director -
Mark C. Mc Kenna,
President, Salix -
Holdings, L.P.Value Act Hol...,
-
Brett Icahn,
Director -
Steven D Miller,
Director -
Tom George Vadaketh,
EVP, Chief Financial Officer -
Holdings, L.P.Value Act Cap...,
-
Aimee J. Lenar,
EVP, US Pharma -
Seana Carson,
EVP, General Counsel -
David Robert Value Act Hold...,
-
Sam Eldessouky,
EVP & Chief Financial Officer -
Frederick Munsch,
SVP, Controller and CAO -
Robert Spurr,
President, U.S. Businesses -
Richard Mulligan,
Director -
John S Barresi,
SVP, Controller & CAO -
Jean Jacques Charhon,
EVP, CFO